



## **FOR IMMEDIATE RELEASE**

### **PMCK POSTS RM5.76 MIL NET PROFIT IN 2QFY26 ON HIGHER INPATIENT VOLUMES AND NET GAIN FROM THE SETTLEMENT**

- **Declares maiden dividend**

Alor Setar, 23 December 2025 - Private healthcare services provider PMCK Berhad (“PMCK” or the “Group”, Bursa: 0363) (“PMCK有限公司”), recorded a net profit of RM5.76 million for the second quarter ended 31 October 2025 (“2QFY26”), supported by stronger inpatient volumes, improved cost efficiency and net gain from the settlement relating to undelivered COVID-19 vaccines.

Revenue for the quarter stood at RM25.42 million, driven mainly by higher inpatient admissions and improved bed occupancy rates. Inpatient care remained the Group’s primary revenue contributor, accounting for about 79.15% of total revenue, while healthcare support services contributed approximately 70.74%.

Gross profit for the quarter stood at RM9.57 million, translating into a gross profit margin of about 37.65%, reflecting an improved patient mix and better cost absorption amid higher activity levels.

On a quarter-on-quarter basis, net profit rose significantly from RM0.84 million in 1QFY26, supported by higher patient volumes, lower administrative expenses and listing expenses as well as a RM3.00 million net gain from the settlement relating to undelivered COVID-19 vaccines.

For the six months ended 31 October 2025 (“1HFY26”), PMCK reported revenue of RM47.18 million and net profit of RM6.60 million, with earnings per share of RM0.62.

As at 31 October 2025, PMCK's total assets expanded to RM196.08 million, compared with RM122.69 million as at 30 April 2025, following its initial public offering ("IPO"). Shareholders' equity strengthened to RM155.07 million, up from RM90.52 million previously, while net assets per share improved to RM0.14 from RM0.11. PMCK also maintained a solid cash and investments position of RM93.05 million.

The Board declared a first interim dividend of 0.12 sen per share, amounting to RM1.31 million for the financial year ending 30 April 2026. The dividend will be paid on 28 January 2026, with the entitlement date set for 9 January 2026.

Commenting on the results, Dato' Lee Gaik Cheng (拿督李伊卿), Managing Director of PMCK Berhad, said the Group's performance reflected steady demand for private healthcare services and improving operational momentum.

"We are encouraged by the Group's second-quarter performance, which was underpinned by higher inpatient volumes, better bed occupancy and a more normalised cost structure following our listing. The contribution from the Hospital Services Outsourcing Programme ("HSOP") also provided additional support during the quarter," she said.

"In terms of our growth strategy, we are prudently assessing selective merger and acquisition opportunities to complement our existing operations, with any potential transactions to be pursued only where there is clear strategic alignment and financial merit," she added.

Meanwhile, the RM6.01 million settlement relating to undelivered COVID-19 vaccines remains on track for full receipt by the first quarter of 2026.

Quarter-on-quarter, revenue increased by 16.82% from RM21.76 million in 1QFY26, mainly due to higher inpatient volumes and improved bed occupancy rates. The Group also benefited from its participation in HSOP during the quarter.

Looking ahead, Dato' Lee said PMCK remains cautiously optimistic on its near-term outlook, supported by steady demand for private healthcare services and ongoing public-private collaboration within Malaysia's healthcare sector.

"While the HSOP is scheduled to conclude in December 2025, we expect patient volumes, to remain resilient in the coming quarters, subject to operational conditions," she said.

PMCK will continue to focus on strengthening service capacity through the recruitment of additional specialists, upgrading medical equipment and enhancing its digital hospital systems to improve operational efficiency and patient experience.

At the same time, PMCK is monitoring rising cost pressures across the sector, including higher electricity tariffs and revisions to statutory contributions, while implementing efficiency initiatives to mitigate their impact.

### **About PMCK Berhad**

PMCK Berhad is a private healthcare services provider based in northern Malaysia, offering comprehensive inpatient, outpatient and healthcare support services. The Group operates its flagship Putra Medical Centre in Alor Setar and is expanding with the development of PMC Kulim to meet rising demand for quality healthcare in the region.

-End-

---

**Issued on behalf of PMCK Berhad**

**Media & Investors Contact:**

**Michelle Kuan Public Relations Consultancy**

Michelle Kuan

Mobile: +6012 335 8339

Email: michellekuanirpr@gmail.com